Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
about
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancerCost-effectiveness of lung cancer screening and treatment methods: a systematic review of systematic reviews.A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic reviewCost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III studyEconomic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer.Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC).Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe.Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents.Clinical and economic review of erlotinib in non-small-cell lung cancer.Treatment of lung cancer: will financial issues become a criterion of choice?Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study.
P2860
Q28487847-A7861908-BE92-4F4B-B583-41E757FBB41AQ33814897-1B28E62E-A766-4303-81DF-34C1B22084C0Q34727967-2A25E6A4-0DC5-4696-BAE0-5F1431E25A30Q34742887-3BF1C850-DB4D-4A1D-91BE-A521D28AC002Q34996046-FFFC1141-3249-4DD7-907C-CC8A9D01333EQ35106391-62B6D6C3-68AE-4829-A558-988C0D87ABBCQ35167535-79CD2868-2F16-4C9A-950C-B79F41F1C2F0Q35429767-B731F190-1584-40FF-91C7-5ACDDA32A711Q36138536-E2159163-8E7B-46C6-A8D1-EFAB7B33EE1CQ36248579-AE733A30-7777-43D4-B09D-DED9DCFE7D5BQ36765647-FCB48694-95C1-47FA-A328-B8528B0F2AA6Q38042709-689E62E0-5E67-499E-9D47-543090D57744Q45833913-51BC24E9-1FEF-4493-95E8-2D2CB573F776Q50238133-29D6E184-7732-4410-A942-4A3E44AEB661Q51290257-E37ADD94-0F61-4D8D-9719-0FAC1945913A
P2860
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cross-market cost-effectivenes ...... ble non-small cell lung cancer
@ast
Cross-market cost-effectivenes ...... ble non-small cell lung cancer
@en
type
label
Cross-market cost-effectivenes ...... ble non-small cell lung cancer
@ast
Cross-market cost-effectivenes ...... ble non-small cell lung cancer
@en
prefLabel
Cross-market cost-effectivenes ...... ble non-small cell lung cancer
@ast
Cross-market cost-effectivenes ...... ble non-small cell lung cancer
@en
P2093
P2860
P50
P356
P1476
Cross-market cost-effectivenes ...... ble non-small cell lung cancer
@en
P2093
David F Heigener
Helge G Bischoff
Joshua A Ray
Stefan Walzer
P2860
P356
10.2147/CEOR.S25923
P407
P577
2012-01-26T00:00:00Z